source
- With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug developmentAI is quickly becoming a central force in drug development, from powering pharma engines to permanently rewiring the capital markets.BioSpace · 19m ago↗ source
- Eli Lilly fronts $2 billion for vaccine biotech deals as Infinimmune secures $75 million fundingEli Lilly announced it has paid $2 billion up front as part of its ongoing strategy to acquire vaccine‑focused biotechnology companies, a portion of a larger deal that could total up to $3.8 billio…